Value Of18f-Fdg PET in Clinical Staging of Non-Small Cell Lung Cancer

Suwen Liu,Jinming Yu,Ligang Xing

DOI: https://doi.org/10.1007/bf02761528

2005-01-01

Abstract:To evaluate the feasibility of18F-deoxyglucose positron emission tomography (18F-FDG PET) in the staging of non-small cell lung cancer (NSCLC).

What problem does this paper attempt to address?

[Value of 18F-Fluorodeoxyglucose Positron Emission Tomography Imaging in Staging of Non-Small Cell Lung Cancer].

Y Guan,S He,J Dong

2001-01-01

Abstract:OBJECTIVE:To evaluate the accuracy and value of fluorine desoxy-glucose Positron emission tomography (FDG PET) imaging in the staging of non-small cell lung cancer (NSCLC).METHODS:A retrospective analysis of 82 patients with NSCLC confirmed by pathological examination was made to study the staging of whole-body FDG PET scanning compared with computerized tomography (CT).RESULTS:The intake of FDG increased in the lung and metastatic foci among all 82 NSCLC patients. Whole-body PET scanning showed concentrated FDG in the 41 NSCLC patients with extrathoracic metastasis. The sensitivity and specificity of FDG PET in prediction of metastasis of mediastinal lymph nodes in patients with lung cancer were 94.4% and 100% respectively. The accuracy of PET scanning in staging of NSCLC was 95.2% in 42 patients who underwent operation after PET imaging. 37 NSCLC patients (45.1%) were restaged after the whole-body FDG PET scanning and their treatment programs were changed.CONCLUSION:PET is more advantageous in pre-operational staging of NSCLC than other conventional imaging techniques, such as CT. For accurate positioning, PET should be combined with anatomical imaging techniques.
PET/CT in the Staging of the Non-Small-Cell Lung Cancer

Fangfang Chao,Hong Zhang

DOI: https://doi.org/10.1155/2012/783739

2012-01-01

Abstract:Lung cancer is a common disease and the leading cause of cancer-related death in many countries. Precise staging of patients with non-small-cell lung cancer plays an important role in determining treatment strategy and prognosis. Positron emission tomography/computed tomography (PET/CT), combining anatomic information of CT and metabolic information of PET, is emerging as a potential diagnosis and staging test in patients with non-small-cell lung cancer (NSCLC). The purpose of this paper is to discuss the value of integrated PET/CT in the staging of the non-small-cell lung cancer and its health economics.
Pre-Radiotherapy Assessment Of Non-Small Cell Lung Cancer With F-18-Flt Pet/Ct Or F-18-Fdg Pet/Ct

Xiaoting Xu,Liangqin Nie,Yimin Yao,Yu Tu,Juying Zhou

2016-01-01

Abstract:Purpose: To evaluate the pre-radiotherapy assessment of F-18-FDG PET/CT in patients with non-small cell lung cancer (NSCLC) in comparison wiht F-18-FLT PET/CT. Methods and materials: A total of fourteen patients were enrolled and underwent both F-18-FDG and F-18-FLT PET/CT. For visualized primary tumors, the maximum and mean standardized uptake value (SUVmax and SUVmean) was calculated. Nodal stages and metastasis were determined by using the American Joint Committee on Cancer (AJCC) staging system. Target volumes were delineated using both F-18-FDG and F-18-FLT PET/CT. In addition, we compared the simulation plans using the optimal threshold of F-18-FDG and F-18-FLT PET/CT. The radiation dose was prescribed as 60 Gy in 30 fractions with a precise radiotherapy technique. Results: F-18-FLT PET/CT instead of F-18-FDG PET/CT detected the lymph node and metastasis in the mediastinal regions of two patients and bone metastasis in another two patients. The SUVmax and SUVmean of F-18-FDG was significantly higher than F-18-FLT (8.12 vs 4.96, 7.05 vs 3.51; P < 0.01, respectively). Target volumes of F-18-FLT PET/CT including gross tumor volume (GTV), clinical target volume (CTV) and planning target volume (PTV) (29.31 vs 38.03 cm(3), 166.47 vs 189.28 cm3, 233.71 vs 269.94 cm(3); P < 0.05, respectively) were smaller than F-18-FDG PET/CT. F-18-FLT PET/CT-based radiotherapy treatment planning had the lower radiation dose to the normal lungs, esophagus and heart than F-18-FDG PET/CT. Conclusion: F-18-FLT PET/CT showed better accuracy for TNM staging than F-18-FDG PET/CT. F-18-FLT PET/CT could more precisely delineate GTV, CTV and PTV than F-18-FDG PET/CT. Moreover, F-18-FLT PET/CT-based radiotherapy treatment planning could provide more protective benefits to the normal lungs, esophagus and heart than F-18-FDG PET/CT.
18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer

Fengxian Zhang,Xiaodong Wu,Junjie Zhu,Yan Huang,Xiao Song,Lei Jiang

DOI: https://doi.org/10.1007/s00259-021-05260-z

2021-02-25

Abstract:This study retrospectively investigated the clinical utility of 2-deoxy-18F-fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) and circulating tumor cells (CTCs) in the diagnosis and prognosis of treatment-naive patients with non-small-cell lung cancer (NSCLC).

radiology, nuclear medicine & medical imaging
Pre-radiotherapy assessment of non-small cell lung cancer with 18 F-FLT PET / CT or 18 F-FDG PET / CT

Xiaoting Xu,Liangqin Nie,Yimin Yao,Yu Tu,Juying Zhou

2016-01-01

Abstract:Purpose: To evaluate the pre-radiotherapy assessment of 18F-FDG PET/CT in patients with non-small cell lung cancer (NSCLC) in comparison wiht 18F-FLT PET/CT. Methods and materials: A total of fourteen patients were enrolled and underwent both 18F-FDG and 18F-FLT PET/CT. For visualized primary tumors, the maximum and mean standardized uptake value (SUVmax and SUVmean) was calculated. Nodal stages and metastasis were determined by using the American Joint Committee on Cancer (AJCC) staging system. Target volumes were delineated using both 18F-FDG and 18F-FLT PET/CT. In addition, we compared the simulation plans using the optimal threshold of 18FFDG and 18F-FLT PET/CT. The radiation dose was prescribed as 60 Gy in 30 fractions with a precise radiotherapy technique. Results: 18F-FLT PET/CT instead of 18F-FDG PET/CT detected the lymph node and metastasis in the mediastinal regions of two patients and bone metastasis in another two patients. The SUVmax and SUVmean of 18F-FDG was significantly higher than 18F-FLT (8.12 vs 4.96, 7.05 vs 3.51; P < 0.01, respectively). Target volumes of 18F-FLT PET/CT including gross tumor volume (GTV), clinical target volume (CTV) and planning target volume (PTV) (29.31 vs 38.03 cm3, 166.47 vs 189.28 cm3, 233.71 vs 269.94 cm3; P < 0.05, respectively) were smaller than 18F-FDG PET/CT. 18F-FLT PET/CT-based radiotherapy treatment planning had the lower radiation dose to the normal lungs, esophagus and heart than 18F-FDG PET/CT. Conclusion: 18F-FLT PET/CT showed better accuracy for TNM staging than 18F-FDG PET/CT. 18F-FLT PET/CT could more precisely delineate GTV, CTV and PTV than 18F-FDG PET/CT. Moreover, 18F-FLT PET/CT-based radiotherapy treatment planning could provide more protective benefits to the normal lungs, esophagus and heart than 18F-FDG PET/CT.
Prognostic Evaluation of Patients with Non-Small Cell Lung Cancer by Using Semi-Quantitative Metabolic Parameters of 18F-FDG PET/CT

Chen Ting,Zhang Hong,Tian Mei

DOI: https://doi.org/10.3760/cma.j.issn.1673-4114.2018.03.014

2018-01-01

Abstract:Accurate diagnosis and prognostic evaluation are essential for the management of patients with non-small cell lung cancer(NSCLC).PET/CT,as a new imaging modality which can provide functional and anatomical imaging simultaneously,plays an important role in theranostics of these patients.This review focuses on the prognostic evaluation of patients with NSCLC by using semi-quantitative metabolic parameters of 18F-FDG PET/CT.
Diagnostic Value of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography/computed Tomography for the Detection of Metastases in Non–small‐cell Lung Cancer Patients

Yihua Wu,Peiwei Li,Honghe Zhang,Yu Shi,Han Wu,Jinjie Zhang,Yufeng Qian,Chao Li,Jun Yang

DOI: https://doi.org/10.1002/ijc.27779

2012-01-01

International Journal of Cancer

Abstract:In the recent years, fluorine 18 fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET)/computed tomography (CT) has emerged as a new modality for staging non-small-cell lung cancer (NSCLC) patients. The aim of this meta-analysis was to assess the diagnostic value of (18)F-FDG PET/CT in detecting metastatic lesions in NSCLC patients. Meta-analysis methods were used to pool sensitivity, specificity, positive and negative likehood ratios, diagnostic odd ratios and to construct a summary receiver-operating characteristic curve. Data from included studies were pooled to compare the diagnostic accuracy between PET/CT and PET or CT alone in nodal staging. Totally, 56 studies involving 8,699 patients met the inclusion criteria. The pooled sensitivities and specificities of (18)F-FDG PET/CT were 0.72 [95% confidence interval (CI): 0.65-0.78] and 0.91 (95% CI: 0.86-0.94) in determining mediastinal nodal staging; 0.71 (95% CI: 0.60-0.80) and 0.83 (95% CI: 0.77-0.88) in intrathoracic staging; 0.78 (95% CI: 0.64-0.87) and 0.90 (95% CI: 0.84-0.94) in intrathoracic staging on a per-node basis. For detecting extrathoracic metastases, the pooled sensitivities and specificities of (18)F-FDG PET/CT were 0.77 (95% CI: 0.47-0.93) and 0.95 (95% CI: 0.92-0.97) for all extrathoracic metastases; 0.91 (95% CI: 0.80-0.97) and 0.98 (95% CI: 0.94-0.99) for bone metastases. (18)F-FDG PET/CT is beneficial in detecting lymph node metastases and extrathoracic metastases although PET/CT showed low sensitivity in detecting brain metastases. (18)F-FDG PET/CT confers significantly higher sensitivity and specificity than contrast-enhanced CT (both p < 0.01) and higher sensitivity than (18)F-FDG PET in staging NSCLC (p < 0.05).
Prognostic Value of 2-[18F]fluoro-2-deoxy-d-glucose Uptake As Measured by PET Scan in Patients with Non-Small Cell Lung Cancer.

Xiang Chen,Jun Zhao,Yi-Hui Guan,Shun Lu,Chuan-Tao Zuo,Feng-Chun Hua,Xiangtong Lin

DOI: https://doi.org/10.3892/mmr_00000046

IF: 3.423

2008-01-01

Molecular Medicine Reports

Abstract:This study aimed to evaluate the prognostic value of 2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG) uptake determined by positron emission tomography (PET) in patients with non-small cell lung cancer (NSCLC) in relation to disease stage and/or tumor histology. A retrospective review of 144 patients with newly diagnosed lung cancer undergoing PET imaging was performed. Differences in survival were compared by univariate and multivariate analyses. Univariate analysis identified three prognostic factors: stage, lesion size and the standardized 18F-FDG uptake value. The latter was a better prognostic predictor in lung cancer patients with early-stage disease than in those at advanced stages. Multivariate analysis revealed that the most important prognostic factors were tumor-node-metastasis (TNM) stage and the standardized 18F-FDG uptake value. Patients with standardized uptake values (SUVs) >8 had a 2.5 times higher mortality rate than those with values ≤8. A one-unit increase in SUV corresponded with a 7% increase in the hazard of death. SUVs provided stronger prognostic stratification in patients with adenocarcinoma than in those with squamous cell carcinoma (SCC). Furthermore, the best choice of prognostic predictor differed between the two types of lung cancer: the SUV was best for SCC, while TNM stage was most significant for adenocarcinoma. In conclusion, 18F-FDG uptake in primary lung lesions is an independent prognostic predictor in patients with NSCLC, especially those with adenocarcinoma or early-stage disease. Further stratification of patients with the same TNM stage based on SUVs may allow for the modification of individual treatment strategies, resulting in improved outcome.
Evaluation of lung lesions using FDG γ-camera PET equipped with a one-inch crystal

Hong-Wei Zhan,Hai-Feng Cheng,Xiao-Juan Ye,Chun-Lei Zhao,Hong Zhang,Hong-Biao Liu,Gang-Qiang He

DOI: https://doi.org/10.3892/or.20.1.173

2008-01-01

Oncology Reports

Abstract:The aim of this study was to evaluate the clinical value of 18-fluorodeoxyglucose (FDG) imaging with gamma-camera positron emission tomography (GCPET) equipped with a one-inch crystal for diagnosing lung lesions and determining the stage of non-small cell lung cancer (NSCLC) in regions with a high prevalence of inflammatory disease and tuberculosis. FDG-GCPET was used to examine 103 patients with suspected malignant lesions in the lung. The results of FDG-GCPET and conventional workup (CWU) including computed tomography (CT), ultrasonography and radionuclide bone scintigraphy were compared. The final diagnosis was based on the results of a histological analysis or follow-up of at least six months. The results showed 82 patients with malignant and 21 patients with benign lesions. If a lesion to background ratio > or = 2.0 was used as the threshold, then the diagnostic sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) of FDG-GCPET for NSCLC were 93.9, 57.1, 86.4, 89.5 and 70.6%, respectively. In 36 patients who underwent open-chest surgery, the diagnostic positive values of FDG-GCPET and CT for lymph-node involvement were 85% (17/20) and 65% (13/20), respectively. The diagnostic sensitivity, specificity, accuracy, PPV and NPV of FDG imaging were 85, 81.3, 83.3, 85 and 81.3%, respectively compared to the CT values of 65, 75, 69.4, 76.5 and 63.2%, respectively (NS). For the evaluation of distant metastases, 31 true-positive patients were identified during the follow-up. FDG imaging correctly identified 28 patients compared to 25 by CWU. In conclusion, FDG imaging with GCPET equipped with a one-inch crystal revealed a high lesion detection capability but a low level of clinical effectiveness for differentiating between malignant and benign lesions in the lung in regions with a high prevalence of inflammatory disease and tuberculosis. For N and M staging of NSCLC, this method may provide additional data that are not available from the CWU.
Quantitative F-18-FDG PET Analysis in Survival Rate Prediction of Patients with Non-Small Cell Lung Cancer

Wenchao Ma,Minshu Wang,Xiaofeng Li,Hui Huang,Yanjia Zhu,Xiuyu Song,Dong Dai,Wengui Xu

DOI: https://doi.org/10.3892/ol.2018.9166

2018-01-01

Oncology Letters

Abstract:The aim of the present study was to investigate the prognostic value of quantitative [F-18]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) parameters for patients with non-small cell lung cancer (NSCLC). The present study conducted a retrospective review of the medical records of 203 patients with NSCLC, of which 193 patients underwent baseline F-18-FDG PET/CT prior to initial therapy. Multivariate analyses using Cox's proportional hazards regression were performed for the assessment of the association between initial PET/CT measurements and overall survival (OS). The multivariate models were adjusted for sex, age, smoking status, disease stage, standardized uptake value (SUV), standardized uptake value corrected for lean body mass (SUL), metabolic tumor volume (MTV), total lesion glycolysis (TLG) and standard deviation of SUV (SD). Kaplan-Meier (K-M) estimator curves were constructed following the formation of three approximately equal-sized groups using tertiles for each PET/CT measurement (n=65, 64 and 64). OS curves were plotted using K-M estimator curves. Results demonstrated significant associations between OS and MTVPET volume computerized assisted reporting (PETVCAR), MTV2.5, MTV25%, MTV42% and TLG(PETVCAR); however, no significant associations were identified between OS and MTV50%, MTV75%, TLG2.5, all SUV and SUL. Subgroup analyses according to pathology demonstrated that there were statistically significant associations between OS and stage (P<0.001), MTV50% (P=0.002) and MTV42% (P=0.004) in the adenocarcinoma group, and SULmean (P=0.010), MTV25% (P=0.005) and MTV42% (P=0.001) in the squamous cell carcinoma group; however, no significant differences were identified between any other group. Furthermore, there was a significant association between OS and MTV42% (P=0.02) and MTV50% (P=0.04) in the early-stage group; however, no significant differences were identified in the advanced-stage group. K-M estimator curve analyses demonstrated that the pathology (P=0.01), stage (P<0.001) and all PET metabolic parameters with the exception of SD were significantly associated with OS (P<0.05). No significant associations were demonstrated between SD and OS. In conclusion, F-18-FDG PET/CT MTVPETVCAR, MTV2.5, MTV25%, MTV42% and TLG(PETVCAR) exhibit prognostic values with regard to OS. Overall, selection of appropriate metabolic parameters may predict NSCLC prognosis.
Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the Evaluation of Patients With Newly Diagnosed Non-Small Cell Lung Cancer

Junhao Wu,Hao Deng,Haoshu Zhong,Tao Wang,Zijuan Rao,Yingwei Wang,Yue Chen,Chunyin Zhang

DOI: https://doi.org/10.3389/fonc.2022.924223

IF: 4.7

2022-07-04

Frontiers in Oncology

Abstract:Purpose: Several studies have demonstrated that 68 Ga-FAPI PET/CT shows high intratumoral tracer uptake and low normal tissue uptake, allowing for excellent visualization of cancer. The purpose of this study was to compare the ability of 68 Ga-FAPI and 18 F-FDG PET/CT for the evaluation of newly diagnosed NSCLC. Materials and Methods: A prospective analysis of 28 individuals with histopathologically newly confirmed NSCLC that underwent 68 Ga-FAPI and 18 F-FDG PET/CT was conducted. The performance of two imaging modalities was compared based upon visual assessment, rates of cancer detection, and semi-quantitative parameters (target-to-background ratio [TBR], maximum standard uptake value [SUVmax]) for both primary tumors and metastases. Results: In total, this study enrolled 28 participants (13 male, 15 female; median age: 60.5 years, range: 34 – 78 years. For primary tumors, 68 Ga-FAPI and 18 F-FDG PET/CT have similar detection performance (28 vs. 27). However, 68 Ga-FAPI PET/CT was found to more effectively evaluate most metastases as compared to 18 F-FDG PET/CT. 68 Ga-FAPI PET/CT detecting more metastases present within the lymph nodes (53 vs. 49), pleura (8 vs. 7), liver (4 vs. 1), and bone (41 vs. 35). The SUVmax and TBR values for 68 Ga-FAPI were substantially superior to those for 18 F-FDG in lymph node, pleural, and bone metastases. While the SUVmax for these two imaging approaches was comparable for hepatic metastases, 68 Ga-FAPI exhibited a significantly higher TBR in relation to that of 18 F-FDG. In addition, 68 Ga-FAPI PET/CT demonstrates excellent N (80% [8/10]) and M (92.9% [26/28]) staging accuracy in NSCLC patients. Conclusions: 68 Ga-FAPI PET/CT as an examination modality is excellent for evaluation of newly diagnosed NSCLC. 68 Ga-FAPI PET/CT improves the detection rates of most metastases and facilitating the superior staging of patients with newly diagnosed NSCLC, relative to that achieved by 18 F-FDG PET/CT.

oncology
Comparison of 18F-Fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer.

Ling Li,Man Hu,Hui Zhu,Wei Zhao,Guoren Yang,Jinming Yu

DOI: https://doi.org/10.3816/CLC.2010.n.042

IF: 4.84

2010-01-01

Clinical Lung Cancer

Abstract:The aim of this study was to compare glucose metabolism and hypoxia using 18F- fluorodeoxyglucose (18F-FDG) and 18F-fluoroerythronitroimidazole (18F-FETNIM) positron emission tomography (PET) and investigate their prognostic role on survival in patients with locally advanced non-small-cell lung cancer (NSCLC).Twenty-six patients with NSCLC were imaged with 18F-FETNIM PET/computed tomography (CT), and 11 cases also with 18F-FDG PET/CT imaging among those with significant 18F-FETNIM uptake, a few days before any chemo/adiation therapy. The maximum standardized uptake value (SUVmax) was used to depict 18F-FDG uptake, and hypoxic volume (HV) and tumor:blood ratio (T/Bmax) were used to quantify hypoxia. Overall survival (OS) after treatment was selected as the endpoint of the study.Twenty-two patients (84.6%) had significant 18F-FETNIM uptake in the primary tumor. The correlations between the overall tumor SUVmax of 18F-FDG and HV, T/Bmax ratio of 18F-FENTIM in 11 patients were small and without significant difference. In univariate analyses, log-rank tests were used to compare Kaplan-Meier survival curves. 18F-FETNIM T/Bmax ratio and HV were strong predictors for OS, and 18F-FDG uptake of the primary lesions did not have a significant relationship with survival. In multivariate survival analysis, only 18F-FETNIM T/Bmax ratio was found to be an independent prognostic factor.Imaging using both 18F-FETNIM and 18F-FDG appears to be beneficial in the evaluation of solid tumors. 18F-FETNIM imaging provides us with a valuable method to detect tumor hypoxia and predict OS. These preliminary results warrant validation in larger trials.
PET with 18F-fluorodeoxyglucose for staging of non-small cell lung cancer

W A Weber,M Dietlein,D Hellwig,C-M Kirsch,H Schicha,M Schwaiger,M. Dietlein,D. Hellwig,C.-M. Kirsch,H. Schicha,M. Schwaiger,W. A. Weber

DOI: https://doi.org/10.1055/s-0038-1625183

2003-01-01

Nuklearmedizin

Abstract:Summary: Aims: To evaluate studies on the use of positron emission tomography with the glucose analog 18F-fluorodeoxyglucose (FDG-PET) for the preoperative staging of patients with non-small cell lung cancer (NSCLC) according to the criteria of evidence based medicine and to discuss the cost-effectiveness of the technique. Methods: Clinical studies published between 1995 and 2002 on the preoperative staging of non-small cell lung cancer were used for this analysis. Studies that did not meet the criteria published by the European Agency for the Evaluation of Medicinal Products (EMEA) were excluded. The validity of the studies was evaluated by a standardized rating system developed by the Agency for Health Care Policy and Research (AHCPR). Results: For the detection of mediastinal lymph node metastases the mean sensitivity and specificity of FDG-PET on a patient basis is 85% and 87% (16 studies, 1355 patients). In studies that compared FDG-PET and computed tomography (CT) the mean sensitivity of CT was 66% at a specificity of 71%. In the detection of distant metastases FDG-PET correctly changed the tumor stage in 18% of the patients when compared to CT based staging (10 studies, 1073 patients). Five cost effectiveness analyses from the USA, Japan, and Germany concluded that FDG-PET improves the outcome of treatment at reduced or only slightly increased overall costs. Improvement of patient outcome was also demonstrated in a randomized trial, which found that the risk of a futile thoracotomy was reduced by 51% (p = 0.003) when FDG-PET was added to the preoperative staging. Conclusion: According to the criteria of the AHCPR the use of FDG-PET for detection of mediastinal lymph node and distant metastases is documented at a level of evidence Ia and Ib, respectively. Since systematic analyses also indicate a favorable cost-effectiveness ratio FDG-PET has to be considered as ”strictly indicated“ for the preoperative staging of non-small cell lung cancer.
18FDG PET/CT in therapeutic assessment and prognostic of non-small cell lung cancer

吴颖,宋勇,施毅

DOI: https://doi.org/10.3760/CMA.J.ISSN.1673-436X.2008.01.008

2008-01-01

Abstract:PET/CT实现了CT解剖结构与PET代谢信息的融合,提高了肺癌诊断的敏感性及特异性,已经广泛用于肺癌的TNM分期.越来越多研究显示它在评估肺癌化放疗疗效及判断预后也有应用前景.目前研究示18FDG PET/CT可以早期准确评估肺癌患者化放疗后疗效,但PET机型,疗效评估最佳时间及评价标准尚未统一.回顾性研究提示原发肿瘤的标准摄取值(standard uptake value,SUV)可能是肿瘤生物侵袭性的预后因子,但需大样本的前瞻性研究证实,并探讨其潜在细胞机制及确定其作为预后的18FDG摄取阈值。
Clinical Evaluation of (18)F-FDG-SPECT/CT Imaging in Diagnosis and Staging of Patients with Suspected Lung Cancer

Zheng Ruan,Jian Zheng,Hailong Huang,Wenrui Zhang,Jinhua Zhao

DOI: https://doi.org/10.3779/j.issn.1009-3419.2005.02.10

2005-01-01

Abstract:Background and objective Correct diagnosis is very important to patients with suspected lung cancer. According to the higher 18 F-FDG intake of tumor tissues much more than normal tissues, this study evaluates the clinical value of 18 F-FDG dual-head coincidence SPECT/CT in diagnosis of lung cancer. Methods Sixty-one patients with lung mass underwent 18 F-FDG dual-head coincidence SPECT/CT imaging and thoracic CT imaging before operation. These imageological results were compared with histological examination of lung mass. Results The sensitivity, specificity and accuracy of 18 F-FDG-SPECT/CT in differentiating malignant and benign lesions were 82%, 87%, 84%, respectively. Compared with thoracic CT imaging, diagnostic rate of mediastinal lymphatic metastasis was significantly higher by 18 F-FDG-SPECT/CT （52% vs 81%, P < 0.05） . Conclusion Combined functional-anatomical image of 18 F-FDG-SPECT/CT has potential to improve staging and localizing procedures of lung cancer. It is an excellent modality in diagnosis and differential diagnosis of lung cancer. DOI: 10.3779/j.issn.1009-3419.2005.02.10
[Value of (18)F-Fluorodeoxyglucose Positron Emission Tomography/computed Tomography in Early Diagnosis of Lung Cancer].

Fang-lei Liu,Qun-ying Hong,Hong-cheng Shi,Yu-can Gu,Chun-xue Bai

DOI: https://doi.org/10.3760/cma.j.issn.0376-2491.2013.38.004

2013-01-01

Abstract:OBJECTIVE:To evaluate the application value of (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) in early diagnosis of lung cancer.METHODS:Retrospective analyses were conducted for 347 cases of pulmonary space-occupying lesions at Zhongshan Hospital from June 2010 to October 2012. The diagnostic validity of PET/CT and fluorodeoxyglucose maximum standardized uptake value (SUVmax) of lesions were compared respectively. Among different morphological characteristics, pathologic types and levels of tumor markers. The diagnostic value of PET/CT was also evaluated along with serum tumor markers for lung cancer.RESULTS:SUVmax was positively correlated with lesion size (r = 0.484, P < 0.05) and negatively with tumor differentiation degree (r = -0.232, P < 0.01). It was significantly higher in tumor marker positive group than the negative group (10.6 ± 5.5 vs 7.6 ± 5.4, P < 0.05). The diagnostic specificity, sensitivity and accuracy of PET/CT were 50.0%, 96.6% and 89.3% in lung cancer. And the greater the lesion, the higher the diagnostic accuracy (P < 0.05). PET/CT plus serum tumor markers could boost the diagnostic specificity of lung cancer by 30% (P < 0.01).CONCLUSIONS:(18)F-FDG PET/CT has high diagnostic values for early stage pulmonary nodules. It can also suggest the differentiation degree of lung cancer. Combined use of serum tumor markers and (18)F-FDG PET/CT increases the early diagnostic specificity of lung cancer.
Application value of 18 F-FDG PET-CT imaging in lung cancer staging

汪世存,邓克学,潘博,谢强,张依凡

DOI: https://doi.org/10.3969/j.issn.1009-6469.2016.08.026

2016-01-01

Abstract:Objective To explore the diagnostic value of 18 F-FDG PET-CT imaging in lung cancer staging.Methods We analyzed ret-rospectively data of 52 patients who underwent PET-CT imaging in Anhui Provincial Hospital from September 2013 to December 2015 and were finally diagnosed lung cancer.According to the latest TNMstaging,we estimated the influence of PET-CT on lung cancer clini-cal staging,and compared it with the pathological staging.In terms of consistency of two kinds of staging,we used Kappa value.When it comes to the comparison of diagnostic accuracy rate in staging,we used Chi-squared texting.M staging was confirmed from pathology, clinical treatment and follow-up imaging.Results Among the 52 cases of patients with lung cancer,PET-CT resulted in changes in 20 cases’clinical staging (20 /52,38.46%),among which 10 cases of staging increased (10 /52,19.23%)and 10 cases of staging re-duced(10 /52,19.23%).Among the 40 cases of surgical treatment,we compared the PET-CT staging (cTNM)with pathological stag-ing (pTNM)and the diagnostic accuracy rates of four stages from Ⅰ to Ⅳ were 94.44% (17 /18),25.00% (1 /4),44.4% (4 /9) and 77.78% (7 /9).Among the four stages,there were significant differences between stage Ⅰand stage Ⅱ and Ⅲ (P <0.005),and c-TNMstaging and p-TNMstaging had an acceptable consistency (Kappa value =0.589).The total coincidence rate was 72.5%.Con-clusions 18 F-FDG PET-CT has a higher diagnostic value for early lung cancer and distant metastasis,which is helpful in early diagno-sis,early treatment and prognosis of lung cancer,and also has a certain application value in clinical treatment.
Bone Metastasis in Patients with Non-Small Cell Lung Cancer: the Diagnostic Role of F-18 FDG PET/CT

Ningbo Liu,Li Ma,Wei Zhou,Qingsong Pang,Man Hu,Fang Shi,Zheng Fu,Minghuan Li,Guoren Yang,Jinming Yu

DOI: https://doi.org/10.1016/j.ejrad.2009.01.036

IF: 4.531

2009-01-01

European Journal of Radiology

Abstract:PURPOSE:To evaluate the performance of F-18 FDG PET/CT in the detection of bone metastasis in non-small cell lung cancer (NSCLC) patients.MATERIALS AND METHODS:Three hundred and sixty-two consecutive NSCLC patients who underwent F-18 FDG PET/CT scanning were retrospectively analyzed. Each image of PET/CT, combined CT, and PET was performed at 10 separate areas and interpreted blindly and separately. The sensitivity, specificity and accuracy of F-18 FDG PET/CT, combined CT and F-18 FDG PET were calculated and the results were statistically analyzed.RESULTS:Bone metastasis was confirmed in 82 patients with 331 positive segments based on the image findings and clinical follow-up. On patient-based analysis, the sensitivity of F-18 FDG PET/CT (93.9%) was significantly higher than those of combined CT (74.4%) and F-18 FDG PET (84.1%), respectively (p<0.05). The overall specificity and accuracy of combined CT, F-18 FDG PET, and F-18 FDG PET/CT were 90.7%, 93.2%, 98.9% and 87.0%, 91.2%, and 97.8%, respectively (compared with PET/CT, p<0.05). On segment-based analysis, the sensitivity of the three modalities were 79.5%, 94.3%, and 98.8%, respectively (compared with PET/CT, p<0.05). The overall specificity and accuracy of the three modalities were 87.9%, 89.2%, 98.6% and 84.5%, 91.2%, 98.7%, respectively (compared with PET/CT, p<0.05).CONCLUSION:F-18 FDG PET/CT is superior to F-18 FDG PET or combined CT in detecting bone metastasis of NSCLC patients because of the complementation of CT and PET. It is worth noting that the added value of F-18 FDG PET/CT may beneficially impact the clinical management of NSCLC.
Higher Accuracy of [68 Ga]Ga-DOTA-FAPI-04 PET/CT Comparing with 2-[18F]FDG PET/CT in Clinical Staging of NSCLC

Zhou Xin,Wang Shuailiang,Xu Xiaoxia,Meng Xiangxi,Zhang Huiyuan,Zhang Annan,Song Yufei,Zhu Hua,Yang Zhi,Li Nan

DOI: https://doi.org/10.1007/s00259-022-05818-5

2022-01-01

Abstract:This study aimed to explore the clinical staging performance of [68 Ga]Ga-DOTA-FAPI-04 PET/CT compared with that of 2-[18F]FDG PET/CT in non-small cell lung cancer (NSCLC) patients lesion by lesion. A total of 134 diagnosed or suspected NSCLC patients were enrolled in the prospective study (ChiCTR2000038080); they received paired 2-[18F]FDG PET/CT and [68 Ga]Ga-DOTA-FAPI-04 PET/CT. Of these patients, the retrospective analysis of 74 NSCLC patients with pathological results was conducted from primary tumor (T) diagnosis, lymph node (N), and metastatic lesion (M) staging. The imaging characteristics of the lung nodules and suspected metastases were obtained and analyzed, and the staging performance of 2-[18F]FDG PET/CT and [68 Ga]Ga-DOTA-FAPI-04 PET/CT was compared. For T diagnosis, [68 Ga]Ga-DOTA-FAPI-04 showed better diagnostic performance than 2-[18F]FDG in 79 lung nodules of 72 patients, especially for nonsolid and small-dimension adenocarcinoma nodules. For N staging, 98 lymph nodes (LNs) with pathological results in 37 patients were analyzed. The SUVmax of [68 Ga]Ga-DOTA-FAPI-04 in the nonmetastatic LNs was significantly lower than that in the metastatic LNs. Regarding metastatic LN identification, the calculated optimum cut-off value of [68 Ga]Ga-DOTA-FAPI-04 SUVmax was 5.5, and the diagnostic accuracy using [68 Ga]Ga-DOTA-FAPI-04 and 2-[18F]FDG criteria was 94% and 30%, respectively (P < 0.001). For M staging, [68 Ga]Ga-DOTA-FAPI-04 identified more lesions than 2-[18F]FDG (257 vs. 139 lesions) in 14 patients with multiple metastases. Overall, the staging accuracy of [68 Ga]Ga-DOTA-FAPI-04 was better than that of 2-[18F]FDG in 52 patients with different pathological stages [43/52 (82.7%) vs. 27/52 (51.9%), P = 0.001]. Compared with 2-[18F]FDG PET/CT, [68 Ga]Ga-DOTA-FAPI-04 PET/CT demonstrated better staging performance in NSCLC patients with different pathological stages, especially those with localized disease.
Clinical Value of Surgical Staging with Preoperative 18F-FDG PET/CT Evaluation for Mediastinal Lymph Nodes in Lung Cancer

Hong Li,Xiaoming Wang,Weina Xu,Jun Xin,Qiyong Guo

DOI: https://doi.org/10.3760/cma.j.issn.2095-2848.2012.03.005

2012-01-01

Abstract:Objective To investigate the clinical value of preoperative 18 F-FDG PET/CT for surgical staging by evaluating mediastinal lymphadenopathy in lung cancer.Methods Sixty-eight patients with lung cancer underwent both 18F-FDG PET/CT and chest CT.The results of PET/CT and CT were compared with pathologieal results.x2 and t tests were used for data analysis.Results A total of 222 mediastinal lymph nodes were resected in 68 patients and 84 (37.8％) were confirmed as metastases by pathology.The sensitivity,specificity,accuracy,positive and negative predictive values for PET/CT and CT were 71.4％(60/84) vs 48.8％ (41/84),66.7％ (92/138) vs 49.3％ (68/138),68.5％ (152/222) vs 49.1％(109/222),56.6％ (60/106) vs 36.9％ (41/111),79.3％ (92/116) vs 61.3 ％ (68/111),respectively (x2=8.96,8.57,17.19,8.43,8.88,all P＜0.05).The staging consistency of PET/CT with pathology was 73.5％ (50/68),which was significantly higher than that of CT with pathology (41.2％ (28/68) ; x2=14.55,P＜0.01).The identification of N1 and N2 disease was,respectively,66.7％(10/15) and 79.2％(19/24) by PET/CT,13.3％(2/15) and 45.8％(11/24) by CT (x2=8.89 and 5.69,both P＜0.05).The SUVmax of lymph nodes greater than and equal to 10 mm in short diameter was significantly higher than those with short diameters less than 10 mm (5.5±2.8 vs 2.2±0.9,t=5.17,P＜0.05).Conclusion Preoperative 18F-FDG PET/CT is more accurate for evaluating mediastinal lymphadnoepathy and staging in patients with lung cancer than CT,and therefore is more valuable for optimizing the best treatment strategies. Key words: Lung neoplasms; Lymph nodes; Neoplasm staging; Tomography,emission-computed; Tomography,X-ray computed; Deoxyglucose

Value Of18f-Fdg PET in Clinical Staging of Non-Small Cell Lung Cancer

[Value of 18F-Fluorodeoxyglucose Positron Emission Tomography Imaging in Staging of Non-Small Cell Lung Cancer].

PET/CT in the Staging of the Non-Small-Cell Lung Cancer

Pre-Radiotherapy Assessment Of Non-Small Cell Lung Cancer With F-18-Flt Pet/Ct Or F-18-Fdg Pet/Ct

18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer

Pre-radiotherapy assessment of non-small cell lung cancer with 18 F-FLT PET / CT or 18 F-FDG PET / CT

Prognostic Evaluation of Patients with Non-Small Cell Lung Cancer by Using Semi-Quantitative Metabolic Parameters of 18F-FDG PET/CT

Diagnostic Value of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography/computed Tomography for the Detection of Metastases in Non–small‐cell Lung Cancer Patients

Prognostic Value of 2-[18F]fluoro-2-deoxy-d-glucose Uptake As Measured by PET Scan in Patients with Non-Small Cell Lung Cancer.

Evaluation of lung lesions using FDG γ-camera PET equipped with a one-inch crystal

Quantitative F-18-FDG PET Analysis in Survival Rate Prediction of Patients with Non-Small Cell Lung Cancer

Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the Evaluation of Patients With Newly Diagnosed Non-Small Cell Lung Cancer

Comparison of 18F-Fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer.

PET with 18F-fluorodeoxyglucose for staging of non-small cell lung cancer

18FDG PET/CT in therapeutic assessment and prognostic of non-small cell lung cancer

Clinical Evaluation of (18)F-FDG-SPECT/CT Imaging in Diagnosis and Staging of Patients with Suspected Lung Cancer

[Value of (18)F-Fluorodeoxyglucose Positron Emission Tomography/computed Tomography in Early Diagnosis of Lung Cancer].

Application value of 18 F-FDG PET-CT imaging in lung cancer staging

Bone Metastasis in Patients with Non-Small Cell Lung Cancer: the Diagnostic Role of F-18 FDG PET/CT

Higher Accuracy of [68 Ga]Ga-DOTA-FAPI-04 PET/CT Comparing with 2-[18F]FDG PET/CT in Clinical Staging of NSCLC

Clinical Value of Surgical Staging with Preoperative 18F-FDG PET/CT Evaluation for Mediastinal Lymph Nodes in Lung Cancer